Fady Ibraham, Executive Vice President of Research and Development at Cytokinetics Inc, filed a Form 4 on August 18, 2026, reporting the exercise of a stock option and the same-day sale of 3,500 shares of common stock under a Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Ibraham acquired 3,500 shares of common stock on August 18, 2026, at an exercise price of $7.80 per share (transaction code M).
  • Same-day sale: 3,500 shares were disposed of on August 18, 2026, at a price of $75.82 per share (transaction code S).
  • Post-transaction ownership: Ibraham directly holds 153,902 shares of common stock following the reported transactions.
  • Derivative securities: 30,386 non-qualified stock options (right to buy) remain beneficially owned, with an exercise price of $7.80 and an expiration date of February 27, 2028.
  • Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Ibraham's Option Exercise and Share Sale at Cytokinetics

According to the Form 4 filed with the SEC, Fady Ibraham, who holds the title of EVP Research and Development at Cytokinetics Inc (NASDAQ:CYTK), executed two transactions on August 18, 2026. First, he exercised a non-qualified stock option covering 3,500 shares at an exercise price of $7.80 per share. That option had an original exercise date of March 27, 2018, and an expiration date of February 27, 2028, according to the filing.

Immediately following the option exercise, the filing reports that Ibraham disposed of 3,500 shares at $75.82 per share. Both transactions are marked as occurring under a Rule 10b5-1(c) written plan, as indicated by the checkbox selected on the form. After these transactions, Ibraham's direct beneficial ownership of common stock stands at 153,902 shares, per the filing.

In addition to the common stock position, the filing discloses that Ibraham retains 30,386 non-qualified stock options (right to buy) with a $7.80 exercise price, held directly. The Form 4 was signed by John O. Faurescu as attorney-in-fact for Dr. Malik on August 18, 2026.

What Was Disclosed

Cytokinetics EVP Fady Ibraham disclosed the exercise of 3,500 stock options at $7.80 and the sale of the resulting shares at $75.82 on August 18, 2026, leaving him with 153,902 shares and 30,386 remaining options, all under a Rule 10b5-1 plan.